A Systems Nephrology Framework for the Molecular Classification of CKD

Tobias Bohnenpoll, Eric Olson, Mykola Dergai, Jennifer Cox, Simone Romoli, I-Ju Lo, Johannes Pospiech, Krishan Vishnolia, Mark McConnell, Marvin Gunawan, Michaela Bayerlová, Nicolette Honson, Niklas Michel, Nikolas Stroth, Olivier Radresa, Philipp Skroblin, Priyanka Kohli, Seamus Ragan, Shenshen Lai, Steven Bromidge, David Powell, Uwe Andag and Andrew King

Evotec SE and Chinook Therapeutics, 59th ERA Congress, 20.05.2022
A systems nephrology framework for the molecular classification of CKD

Integration of real-world clinical, morphological and molecular data

- Conventional stratification by clinical and histopathological phenotypes is insufficient to describe the heterogeneity of chronic kidney diseases (CKD)

- Integration of intra-renal molecular and morphological features with clinical outcomes is required to drive discovery of disease-modifying therapies

- The NURTuRE biobank comprises matched patient samples from a broad range of diagnoses and kidney functional states, that are associated with rich clinical data

We aim to generate mechanistic disease understanding for a patient-centric, integrated target and biomarker discovery that will enable the development of novel precision treatments

Figure (lower left) adapted from Kidney Precision Medicine Project, accessed 4 May 2022, https://www.kpmp.org/about-kpmp
Unsupervised analysis reveals molecular similarities and transitions that align with disease progression

Definition of molecular clusters and disease trajectories from biopsy transcriptomes

- Unsupervised clustering of kidney transcriptomes via self organizing maps\(^1\) inferred 5 groups with distinct molecular landscapes (F, E, C, A and AB) that were generally consistent with molecular clusters previously described for CKD\(^2\)

- Correlation of metagenes reveals a highly polarized global data structure resulting from strong opposing metabolic and immune signatures (Figure A)

- Molecular stratification aligns with clinical disease progression, but can not be fully explained by conventional parameters (Figure B)

- PHATE\(^3\) dimensionality reduction suggests molecular similarities and transitions that can be interpreted as molecular disease trajectories (Figure C)

Molecular stratification aligns with disease progression irrespective of clinical diagnosis, reflecting common cellular and molecular mechanisms of disease

---


Disease progression rates are non-randomly distributed across molecular clusters and disease trajectories

Integration of eGFR time series

Patient stratification based on longitudinal eGFR decline (representative examples)

Molecular clusters C and A are enriched for patients with progressive disease
Morphological risk factors are non-randomly distributed across molecular clusters and disease trajectories

Integration of free-text histopathology records

Interstitial fibrosis and tubular atrophy (IFTA) gradually increases with molecular disease progression

Acute tubular damage highlights clusters of patients with active disease

IFTA: scoring of affected cortical area; 0 = <5% (none/minimal), 1 = 5-25% (mild), 2 = 25-50% (moderate), 3 = >50% (severe)

Acute tubular damage

FALSE

TRUE
Molecular stratification captures tissue remodeling dynamics in CKD

Exploration of cell type signatures across molecular clusters and disease trajectories

Changes in signature expression indicate tissue remodeling dynamics

A cell-centric map of NURTuRE biopsy transcriptomes
Summary and Outlook

- Unsupervised characterization of NURTuRE kidney transcriptomes inferred 5 clusters with distinct molecular landscapes (F, E, C, A and AB)

- Molecular stratification aligned with clinical and histopathological parameters of disease progression

- Dimensionality reduction suggested transitions between molecular clusters that can be interpreted as pseudotime disease trajectories

- Careful characterization of gene expression and tissue remodeling dynamics along these trajectories will reveal cellular and molecular mechanism of CKD that unfold over years and decades

Gene expression and tissue remodeling dynamics along molecular disease trajectories

Stratify by early, intermediate and late changes

Identify targetable mechanisms of disease
Acknowledgement

Thanks to all members of the Chinook-Evotec Strategic Partnership…

… and all contributors of the NURTuRE Consortium!

Elaine Davies,
Director at Kidney Research UK

Prof. Moin Saleem
University of Bristol

Prof. Maarten Taal
University of Nottingham